Myriad’s Flurizan (correction)
Executive Summary
Flurizan, a selective amyloid lowering agent intended to slow progression of Alzheimer's disease, is currently the only one of its class in Phase III studies. The product's generic name is tarenflurbil, and it is being developed by Myriad Pharmaceuticals; a previous article on Alzheimer's drugs in development misidentified the drug (1"The Pink Sheet" Aug. 13, 2007, p. 10)...